11:00:48 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-11-15 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-06-03 Extra Bolagsstämma 2024
2024-05-16 Kvartalsrapport 2024-Q1
2024-04-17 X-dag ordinarie utdelning PEG 0.00 DKK
2024-04-16 Årsstämma 2024
2024-03-20 Bokslutskommuniké 2023
2023-11-02 Extra Bolagsstämma 2023
2023-08-16 Kvartalsrapport 2023-Q2
2023-04-26 X-dag ordinarie utdelning PEG 0.00 DKK
2023-04-25 Årsstämma 2023
2023-03-31 Bokslutskommuniké 2022
2022-10-27 Extra Bolagsstämma 2022
2022-08-31 Kvartalsrapport 2022-Q2
2022-04-26 X-dag ordinarie utdelning PEG 0.00 DKK
2022-04-25 Årsstämma 2022
2022-03-31 Bokslutskommuniké 2021
2022-01-21 Bokslutskommuniké 2021
2021-11-10 Extra Bolagsstämma 2021
2021-08-30 Kvartalsrapport 2021-Q2
2021-05-03 X-dag ordinarie utdelning PEG 0.00 DKK
2021-04-29 Årsstämma 2021
2020-08-24 Kvartalsrapport 2020-Q2
2020-04-28 X-dag ordinarie utdelning PEG 0.00 DKK
2020-04-27 Årsstämma 2020
2020-03-30 Bokslutskommuniké 2019
2019-11-01 Split PEG 10:1
2019-08-23 Kvartalsrapport 2019-Q2
2019-04-29 X-dag ordinarie utdelning PEG 0.00 DKK
2019-04-26 Årsstämma 2019
2019-03-29 Bokslutskommuniké 2018
2019-02-26 Extra Bolagsstämma 2019
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-01 X-dag ordinarie utdelning PEG 0.00 DKK
2018-04-30 Årsstämma 2018
2018-04-06 Bokslutskommuniké 2017
2017-08-25 Kvartalsrapport 2017-Q2
2017-05-01 X-dag ordinarie utdelning PEG 0.00 DKK
2017-04-28 Årsstämma 2017
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-12 Kvartalsrapport 2016-Q1
2016-05-02 X-dag ordinarie utdelning PEG 0.00 DKK
2016-04-29 Årsstämma 2016
2016-03-31 Bokslutskommuniké 2015
2016-02-24 Split PEG 1:10
2016-02-18 Extra Bolagsstämma 2016
2015-10-21 Kvartalsrapport 2015-Q3
2015-07-15 Kvartalsrapport 2015-Q2
2015-05-01 X-dag ordinarie utdelning PEG 0.00 DKK
2015-04-30 Årsstämma 2015
2015-04-14 Kvartalsrapport 2015-Q1
2015-03-31 Bokslutskommuniké 2014
2015-02-02 Extra Bolagsstämma 2015
2014-12-22 Extra Bolagsstämma 2014
2014-11-07 Kvartalsrapport 2014-Q3
2014-08-15 Kvartalsrapport 2014-Q2
2014-05-09 Kvartalsrapport 2014-Q1
2014-04-30 Årsstämma 2014
2014-04-01 X-dag ordinarie utdelning PEG 0.00 DKK
2014-03-31 Bokslutskommuniké 2013
2013-11-06 Kvartalsrapport 2013-Q3
2013-08-16 Kvartalsrapport 2013-Q2
2013-05-07 Kvartalsrapport 2013-Q1
2013-04-30 Årsstämma 2013
2013-04-01 X-dag ordinarie utdelning PEG 0.00 DKK
2013-03-29 Bokslutskommuniké 2012
2012-11-06 Kvartalsrapport 2012-Q3
2012-08-17 Kvartalsrapport 2012-Q2
2012-05-07 Kvartalsrapport 2012-Q1
2012-05-01 X-dag ordinarie utdelning PEG 0.00 DKK
2012-04-30 Årsstämma 2012
2012-03-30 Bokslutskommuniké 2011
2011-11-04 Extra Bolagsstämma 2011
2011-05-02 X-dag ordinarie utdelning PEG 0.00 DKK
2011-04-29 Årsstämma 2011
2010-05-03 X-dag ordinarie utdelning PEG 0.00 DKK


ListaSmall Cap Copenhagen
Pharma Equity Group utvecklar nya läkemedel för lokal behandling av allvarliga och livshotande inflammatoriska sjukdomar för vilka det för närvarande inte finns någon adekvat behandling. Bolaget använder ompositionering av befintliga läkemedel och tar läkemedelskandidater till ett kliniskt fas III-stadium, varefter de överlämnas till en strategisk partner som kommer att slutföra utvecklingen av produkterna och föra ut dem på marknaden, antingen självständigt eller i samarbete med bolaget.
2024-06-03 16:17:47
 Results of extraordinary general meeting in Pharma Equity Group A/S

3 June 2024
Company announcement no. 19


Pharma Equity Group A/S today held an extraordinary general meeting with the following results:


  1. The company's share capital will be reduced by a nominal value of DKK 920,667,494.70 from a nominal value of DKK 1,022,963,883.00 to a nominal value of DKK 102,296,388.30 by allocation to a specific reserve pursuant to section 188(1)(3) of the Danish Companies Act. The capital reduction will be made by a proportional reduction of the denomination of all the company's shares, meaning that the denomination of the shares will be reduced from DKK 1.00 to DKK 0.1.

Prior to the completion of the capital reduction, the company's creditors will be encouraged to give notice on any claims against the company for a period of four weeks. The request will be published in the Danish Business Authority's IT-system.


  1. The chair of the general meeting was, with a right of substitution, authorised to file the resolution adopted with the Danish Business Authority and to make any such amendments as the Danish Business Authority may require to register or approve the resolution adopted.


For further information, please contact:

 Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: +45 4022 2114

Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone: +45 2622 7222

About Pharma Equity Group A/S

Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects.

The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.